AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
CorMedix Acquires Seven Drug Products, Expands Revenue to $305-335mln by 2025.
ByAinvest
Thursday, Aug 7, 2025 7:10 am ET1min read
• CorMedix acquires seven innovative drug products and pipeline expansion. • Expected to be near-term accretive to EPS with double-digit accretion in 2026. • Annual run-rate synergies expected to be $35-$45 million. • Pro forma 2025 combined revenues estimated at $305-$335 million. • Advances CorMedix's strategy for a specialty pharmaceutical business. • Expands platform for additional products and growth.
CorMedix Inc. (Nasdaq: CRMD) has announced the acquisition of seven innovative drug products and pipeline expansion, which is expected to be near-term accretive to earnings per share (EPS) with double-digit accretion in 2026. The company expects annual run-rate synergies of $35-$45 million, with pro forma 2025 combined revenues estimated at $305-$335 million. This acquisition advances CorMedix's strategy for a specialty pharmaceutical business and expands its platform for additional products and growth.The acquisition, which includes Melinta Therapeutics LLC, aims to bolster CorMedix's portfolio and enhance its capabilities in the biopharmaceutical sector. The company reported strong financial results for the second quarter and six months ended June 30, 2025, with net revenue of $39.7 million and net income of $19.8 million, respectively [1].
CorMedix's management team will host a conference call and webcast today, August 7, 2025, at 8:30 a.m. Eastern Time, to discuss the acquisition and recent corporate developments. The call details and dial-in information are as follows: Domestic: 1-844-676-2922, International: 1-412-634-6840, Webcast: Webcast Link.
References:
[1] https://www.globenewswire.com/news-release/2025/08/07/3129077/0/en/Cormedix-Inc-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet